期刊文献+

奥拉西坦注射液对急性脑梗死患者的疗效观察 被引量:8

Treatment of Acute Cerebral Infarction with Oxiracetam Injection
原文传递
导出
摘要 目的观察奥拉西坦治疗急性脑梗死的效果。方法将80例急性脑梗死患者分为两组:治疗组和对照组各40例,治疗组除基础治疗外,加用奥拉西坦注射液4.0g入5%葡萄糖或生理盐水中,每日一次静滴;对照组仅采用常规抗血小板聚集、营养神经,改善微循环等常规治疗,必要时抗凝和对症治疗。一疗程后比较两组显效率、总有效率、神经功能缺损评分及日常生活活动能力评分。结果治疗组和对照组显效率分别为52.50%和35%(P<0.05),总有效率分别为77.50%和55%(P<0.05);与对照组比较,治疗组神经功能缺损评分明显减少(P<0.05),患者日常生活能力明显提高(P<0.05)。结论奥拉西坦有明显地改善急性脑梗死临床神经功能、提高患者日常生活能力的作用。 Objective To investigate effect of oxiracetam on treatment of acute cerebral infarction,Methods Eighty patients with acute cerebral infarction were randomly divided into two groups:the treatment group(40 cases) and the control group(40 cases),The treatment group was given oxiracetam injection of 4.0 g in 5% glucose or nor- mal saline, intravenously once a clay, besides other conventional treatment;the control group was only given conven- tional treatment, e.g,anti-platelet aggregation, nerve nutrition, improvement of mierocireulation, and so on,If nec- essary, anticoagulation and symptomatic treatment were used,After a course of treatment, excellent effective rate and overall effective rate, neurological deficit scores, and the scores of activities of daily life were compared with one an- other,Results Excellent effective rate in the treatment group and the control group were respectively 52.50% and 35%(P<0.05)and the overall effective rate were 77.50% and 55%(P<0.05),Compared with the control group, the scores of neurologie impairment of the treatment group reduced(P<0.05), meanwhile the scores of activities of daily life increased significantly(P<0.05),Conclusion Oxiracetam can significantly neurological function of acute cerebral infarction and the ability of patients in daily life.
出处 《神经病学与神经康复学杂志》 2008年第1期4-6,共3页 Journal of Neurology and Neurorehabilitation
关键词 急性脑梗死 奥拉西坦 疗效 acute cerebral infarction oxiracetam curative effect
  • 相关文献

参考文献4

二级参考文献25

  • 1Parnetti L, Mecocci P, Gaiti A, et al. Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type [J]. Eur J Drug Metab Pharmacokinet, 1990, 15(1): 75-78.
  • 2Ponzio F, Pozzi O, Banfi S, et al. Brain entry and direct central pharmacological effects of the nootropic drug oxiracetam. Oxiracetam: brain entry and pharmacological effects [J]. Pharmacopsychiatry, 1989, 22(Suppl 2): 111-115.
  • 3Banfi S, Dorigotti L, Abbracchio MP, et al. Methylazoxymethanol microencephaly in rats: neurochemical characterization and behavioral studies with the nootropic oxiracetam [J]. Pharmacol Res Commun, 1984, 16(1): 67-83.
  • 4Lecaillon JB, Dubois JP, Coppens H, et al. Pharmacokinetics of oxiracetam in elderly patients after 800 mg oral doses, comparison with non-geriatric healthy subjects [J]. Eur J Drug Metab Pharmacokinet, 1990, 15(3): 223-230.
  • 5Pepeu G, Spignoli G. Nootropic drugs and brain cholinergic mechanisms [J]. Prog Neuropsychopharmacol Biol Psychiatry, 1989, 13(Suppl): S77-88.
  • 6Spignoli G, Pepeu G. Oxiracetam prevents electroshock-induced decrease in brain acetylcholine and amnesia [J]. Eur J Pharmacol, 1986, 126(3): 253-257.
  • 7Spignoli G, Pepeu G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine [J]. Pharmacol Biochem Behav, 1987, 27(3): 491-495.
  • 8Spignoli G, Pedata F, Giovannelli L, et al. Effect of oxiracetam and piracetam on central cholinergic mechanisms and active-avoidance acquisition [J]. Clin Neuropharmacol, 1986, 9(Suppl 3): S39-47.
  • 9Mochizuki D, Sugiyama S, Shinoda Y. Biochemical studies of oxiracetam (CT-848) on cholinergic neurons [J]. Nippon Yakurigaku Zasshi, 1992, 99(1): 27-35.
  • 10Lucchi L, Pascale A, Battaini F, et al. Cognition stimulating drugs modulate protein kinase C activity in cerebral cortex and hippocampus of adult rats [J]. Life Sci, 1993, 53(24): 1821-1832.

共引文献33081

同被引文献73

引证文献8

二级引证文献126

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部